Integrated Islet Distribution Program (U24) - 2021

项目总结/摘要 人类胰岛是研究胰腺癌的预防、治疗和治疗的重要研究资源。 糖尿病的病理生理学最近的数据强调了小鼠和 人类胰岛，证实了对人类胰岛的持续需求，作为糖尿病的金标准 research. City of Hope（COH）正在申请U24更新，以保持其作为综合岛屿分布 计划协调中心（IIDP CC）在未来5年内，继续提供人类 用于生物医学研究的尸体胰岛和辅助组织。我们的提案利用了 NIH在过去19年中所做的重大投资， COH的IIDP。从高质量胰岛隔离中心（IIC）的资格认证和审核，到预测， 跟踪，并满足调查人员的需求，自2002年以来，我们经验丰富的团队已经与20个不同的 胰岛隔离实验室，以协调分配超过3.3亿胰岛当量，以超过400 自2002年以来，在16个国家进行了调查，为767份同行评审出版物提供了支持。通过这次更新， 我们将继续使用我们的5个高质量的IIC来分离和分配人类胰岛和辅助细胞， 通过我们先进的电子胰岛分配系统（IAS）。我们将继续管理审查过程 用于胰岛接收、试点研究和机会池资金。我们将进一步加强我们的国际会计准则， 在线并以公平、公正和及时的方式通知已批准的等待研究人员胰岛的可用性。 IIDP将继续通过向island收取订阅费来维持现有的成本回收系统 研究人员，自实施订阅费以来共获得9，303，950美元，以抵消 IIC的胰腺处理费用。我们会继续密切监察及协助改善 通过人类胰岛表型分析计划（HIPP）的继续， 对来自每个胰岛分离物的样品进行分析。IIDP刚刚增加了人类胰岛基因分型倡议 （HIGI）对每个分离物进行基因分型。表型和基因型数据，以及UNOS数据，广泛 供体和胰岛分离数据，将通过在线访问IIDP提供给批准的研究者 研究数据库，IIDP和NIDDK批准申请科学家。调查人员可以很容易地搜索 所需的数据，选择筛选条件，保存搜索结果，并下载集成的IIDP数据进行探索 分析。通过我们经过验证的最先进的行政，业务，技术，统计，质量保证， 和信息学的过程和工具，人类胰岛的可及性，为研究人员进行必要的 糖尿病研究将得到保障。我们将继续提供不可或缺的研究资源， 通过确保IIDP保持稳定，技术先进， 增强，并充分响应研究界的胰岛需求，促进下一代 糖尿病的预防和治疗的科学实验。

PROJECT SUMMARY / ABSTRACT Human pancreatic islets are an essential research resource for research on the prevention, treatment, and pathophysiology of diabetes mellitus. Recent data have highlighted important differences between murine and human islets, substantiating the continued need for access to human islets, as the gold standard in diabetes research. City of Hope (COH) is applying for this U24 renewal to remain as the Integrated Islet Distribution Program Coordinating Center (IIDP CC) for the next 5 years, to continue to provide distribution of human cadaveric islets and ancillary tissue for biomedical research to researchers worldwide. Our proposal leverages the significant investment made by NIH over the last 19 years that has established and successfully maintained the IIDP at COH. From qualification and auditing of high-quality Islet Isolation Centers (IICs), to forecasting, tracking, and meeting the needs of investigators, since 2002 our experienced team has worked with 20 different islet isolation laboratories to coordinate the distribution of over 330 million islet equivalents to more than 400 investigators across 16 countries since 2002, supporting 767 peer reviewed publications. Through this renewal we will continue to subcontract with our 5 highly qualified IICs to isolate and distribute human islets and ancillary tissue via our advanced electronic Islet Allocation System (IAS). We will continue to manage the review process for islet receipt, pilot studies, and Opportunity Pool funding. We will further enhance our IAS to broadcast offers online and notify approved waiting researchers of islet availability, in a fair, equitable and time sensitive manner. IIDP will continue to maintain the existing cost recovery system through subscription fees collected from islet researchers, which has garnered a total of $9,303,950 since the implementation of subscription fees to offset the expenses of pancreatic processing for the IICs. We will continue to closely monitor and help to improve the quality of islets distributed, through the continuation of the Human Islet Phenotyping Program (HIPP) that conducts assays on a sample from each islet isolation. IIDP has just added a Human Islet Genotyping Initiative (HIGI) to genotype each isolation as well. Phenotyping and genotyping data, as well as UNOS data, extensive donor and islet isolation data, will be made available to approved investigators through online access to the IIDP Research Data Repository, with IIDP and NIDDK approval of applying scientists. Investigators can easily search the required data, select filter criteria, save their searches, and download the integrated IIDP data for exploratory analyses. Through our proven state-of-the-art administrative, business, technical, statistical, quality assurance, and informatics processes and tools, the accessibility of human islets for investigators conducting essential diabetes mellitus research will be secured. We will continue to provide an indispensable research resource for the diabetes research community by ensuring that the IIDP remains stable, technologically advanced, continually enhanced, and fully responsive to the islet needs of the research community, promoting the next generation of scientific experimentation toward the prevention and treatment of diabetes.